GBT
BEAM icon

Grove Bank & Trust’s Beam Therapeutics BEAM Stock Holding History

Grove Bank & Trust’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-53
Closed -$1.27K – 596
2023
Q3 		$1.27K Buy
+53
New +$1.42K ﹤0.01% 677

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Grove Bank & Trust's BEAM Position: Q4 2023 in Review

Grove Bank & Trust sold out of Beam Therapeutics (BEAM) in Q4 2023, closing a stake of 53 shares — an estimated $1.27K sold.

Grove Bank & Trust first reported a position in BEAM in Q3 2023 and held it in 1 quarter. The position peaked at $1.27K in Q3 2023. 185 funds tracked by Wall St. Rank hold BEAM as of Q4 2023.

  • Grove Bank & Trust reported no remaining Beam Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 53 Beam Therapeutics shares in Q4 2023, an estimated $1.27K.
  • Grove Bank & Trust first reported a position in Beam Therapeutics in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's Beam Therapeutics position peaked at $1.27K in Q3 2023.
  • 185 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.